EBS - Emergent BioSolutions Inc.

NYSE - NYSE Delayed Price. Currency in USD
43.58
-0.68 (-1.54%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close44.26
Open44.05
Bid42.34 x 900
Ask44.79 x 800
Day's Range42.81 - 44.12
52 Week Range42.29 - 73.89
Volume294,654
Avg. Volume597,769
Market Cap2.239B
Beta (3Y Monthly)1.46
PE Ratio (TTM)54.34
EPS (TTM)0.80
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est68.67
Trade prices are not sourced from all markets
  • Markit2 days ago

    See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

    Emergent Biosolutions Inc NYSE:EBSView full report here! Summary * Bearish sentiment is low and declining Bearish sentimentShort interest | PositiveShort interest is low for EBS with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 14. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.43 billion over the last one-month into ETFs that hold EBS are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire3 days ago

    Emergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe

    GAITHERSBURG, Md., May 20, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine.

  • GlobeNewswire3 days ago

    Emergent BioSolutions to Participate in Series of Investor Conferences

    GAITHERSBURG, Md., May 20, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the.

  • GlobeNewswire8 days ago

    Emergent BioSolutions Prepares for Initial Shipments of AV7909 Anthrax Vaccine Candidate into the Strategic National Stockpile

    Emergent BioSolutions Inc. (EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has informed the company that it will begin procuring AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) for delivery into the Strategic National Stockpile (SNS). Subject to the fulfillment of certain contractual obligations, the company plans to deliver AV7909 in the second half of 2019 under the terms of its development and procurement contract with BARDA valued at up to $1.5 billion signed in September 2016. This milestone and the initiation of the Phase 3 trial of AV7909 in March build upon the application that was submitted in December 2018 to the U.S. Food and Drug Administration (FDA) for the potential emergency use of AV7909 in the event of a public health emergency involving Bacillus anthracis.

  • 3 Top Healthcare Stocks to Buy in May
    Motley Fool8 days ago

    3 Top Healthcare Stocks to Buy in May

    These look like great picks to buy in May before you go away.

  • GlobeNewswire14 days ago

    Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 23, 2019 at 9:00 AM EDT; Webcast Will Be Available

    GAITHERSBURG, Md., May 09, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 23, 2019 beginning.

  • Emergent BioSolutions Negotiates for a Strong Second Half
    Motley Fool14 days ago

    Emergent BioSolutions Negotiates for a Strong Second Half

    A new government contract for smallpox vaccine, ACAM2000, is still in the works.

  • Thomson Reuters StreetEvents15 days ago

    Edited Transcript of EBS earnings conference call or presentation 2-May-19 9:00pm GMT

    Q1 2019 Emergent BioSolutions Inc Earnings Call

  • 3 Top Biotech Stocks to Buy in May
    Motley Fool16 days ago

    3 Top Biotech Stocks to Buy in May

    These three biotech stocks could be prime comeback candidates.

  • Emergent (EBS) Earnings & Revenues Miss Estimates in Q1
    Zacks20 days ago

    Emergent (EBS) Earnings & Revenues Miss Estimates in Q1

    Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.

  • Why Emergent BioSolutions Stock Is Tanking Today
    Motley Fool20 days ago

    Why Emergent BioSolutions Stock Is Tanking Today

    Shares drop after the company reports first-quarter results that missed the mark.

  • Emergent BioSolutions Inc (EBS) Q1 2019 Earnings Call Transcript
    Motley Fool20 days ago

    Emergent BioSolutions Inc (EBS) Q1 2019 Earnings Call Transcript

    EBS earnings call for the period ending March 31, 2019.

  • New Strong Sell Stocks for May 3rd
    Zacks20 days ago

    New Strong Sell Stocks for May 3rd

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • Emergent Biosolutions (EBS) Reports Q1 Loss, Misses Revenue Estimates
    Zacks20 days ago

    Emergent Biosolutions (EBS) Reports Q1 Loss, Misses Revenue Estimates

    Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -200.00% and -6.88%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press20 days ago

    Emergent Biosolutions: 1Q Earnings Snapshot

    On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 51 cents. Losses, adjusted for non-recurring costs, were 13 cents per share. The results did not meet Wall Street expectations. ...

  • GlobeNewswire21 days ago

    Emergent BioSolutions Reports First Quarter 2019 Financial Results

    Reaffirms full year 2019 financial forecast and operational goalsProvides Q2 2019 revenue forecast of $200M-$220M GAITHERSBURG, Md., May 02, 2019 -- Emergent BioSolutions Inc..

  • What Are Analysts Saying About Emergent BioSolutions Inc.'s (NYSE:EBS) Earnings Trajectory?
    Simply Wall St.23 days ago

    What Are Analysts Saying About Emergent BioSolutions Inc.'s (NYSE:EBS) Earnings Trajectory?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The most recent earnings announcement Emergent BioSolutions Inc.'s (NYSE:EBS) released in December 20...

  • Is Emergent Biosolutions Inc (EBS) A Good Stock To Buy ?
    Insider Monkey27 days ago

    Is Emergent Biosolutions Inc (EBS) A Good Stock To Buy ?

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 13.1% in the 2.5 months of 2019 (including […]

  • Emergent Biosolutions (EBS) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks28 days ago

    Emergent Biosolutions (EBS) Reports Next Week: Wall Street Expects Earnings Growth

    Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • MarketWatchlast month

    FDA approves first generic naloxone nasal spray to treat opioid overdose

    The Food and Drug Administration has given Israeli drugmaker Teva Pharmaceuticals Inc. final approval to market the first generic naloxone nasal spray to treat opioid overdose, the agency announced Friday. The spray, currently sold under the brand name Narcan by Emergent BioSolutions Inc. subsidiary Adapt Pharma, is a life-saving medication that can stop or reverse the effects of an opioid overdose. Shares of Teva have lost 6.9% so far this year, while the S&P 500 has gained 15.9%. Shares of Emergent BioSolutions have fallen 10.6%. This marks the first time a generic naloxone nasal spray has been approved for use by people without medical training, though generic injectable naloxone products have been available for years. "In the wake of the opioid crisis, a number of efforts are underway to make this emergency overdose reversal treatment more readily available and more accessible. In addition to this approval of the first generic naloxone nasal spray, moving forward we will prioritize our review of generic drug applications for naloxone," said Douglas Throckmorton, deputy center director for regulatory programs in the FDA's Center for Drug Evaluation and Research, in a statement. The U.S. in the midst of a deadly opioid epidemic. Almost 400,000 people died from opioid overdose between 1999 and 2017, according to the Centers for Disease Control and Prevention.

  • GlobeNewswirelast month

    Emergent BioSolutions to Release First Quarter 2019 Financial Results and Conduct a Conference Call on May 2, 2019

    GAITHERSBURG, Md., April 18, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, May 2, 2019 at 5:00 pm (Eastern Time) to discuss the.

  • Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study
    Zackslast month

    Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study

    Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.

  • GlobeNewswirelast month

    Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate

    The interim analysis has shown that with a single dose administered, up to 98% of study participants produced a neutralizing antibody response against the chikungunya virus (CHIKV) by Day 7. Further, the immune response was shown to be persistent through the six-month visit, including in the one-dose regimen.

  • What Should We Expect From Emergent BioSolutions Inc.'s (NYSE:EBS) Earnings In The Year Ahead?
    Simply Wall St.last month

    What Should We Expect From Emergent BioSolutions Inc.'s (NYSE:EBS) Earnings In The Year Ahead?

    After Emergent BioSolutions Inc.'s (NYSE:EBS) earnings announcement in December 2018, analysts seem extremely confident, with profits predicted to ramp up by an impressive 72% n...